Effect of SBG in Patients With Breast Cancer

A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00533364

Enrollment

Registered

2007-09-21

Start date

2007-01-31

Completion date

2010-01-31

Last updated

2010-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This study is set up to determine whether soluble beta-glucan (SBG) has * unfavourable side effects * beneficial treatment effects when given in combination with standard antibody and chemotherapy to patients with breast cancer.

Interventions

DRUGSBG (Soluble beta-glucan)

Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Women with histologically/cytologically confirmed locally advanced or metastatic breast cancer 2. Primary tumor or metastases are HER2-ICH3+ or FISH+ 3. Measurable or non-measurable disease 4. The patients must not have received treatment with the combination trastuzumab and vinorelbine previously 5. Expected lifetime of more than 12 weeks 6. Age ≥ 18 years 7. Performance status ≤ 2 according to World Health Organization (WHO) scale 8. The patient must be able to comply with the protocol 9. Verbal and written informed consent

Exclusion criteria

1. Women who are pregnant or breast-feeding. A negative pregnancy test must be provided during the screening period for fertile women. Fertile women must use effective contraceptive methods 2. Clinical symptoms indicating central nervous system involvement 3. Other current or former malignant disease, with the exception of adequately treated and cured carcinoma in situ cervicis uteri and basocellular skin carcinomas 4. Left ventricular ejection fraction (LVEF) \< 50% of normal range 5. Reduced bone marrow function defined by leukocyte counts \< 3.0 x 109/l and neutrophil counts \< 1.5 x 109/l, or thrombocyte counts ≤ 100 x 109/l 6. Reduced liver function defined by bilirubin \> 3 x upper normal limit and/or ASAT/ALAT \> 3 x upper normal limit and/or alkaline phosphatase \> 3 x upper normal limit. 7. Reduced renal function defined by serum creatinine \> 2 x upper normal limit

Design outcomes

Primary

Measure	Time frame
Asess the safety of SBG in combination with standard antibody and chemotherapy treatment	21 weeks

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026